share_log

Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97

Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97

Leerink Partners將藍圖藥物升級至市場表現,將目標股價上調至97美元
Benzinga ·  05/06 13:47

Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and raises the price target from $50 to $97.

Leerink Partners分析師安德魯·貝倫斯將Blueprint Medicines(納斯達克股票代碼:BPMC)從表現不佳上調至市場表現,並將目標股價從50美元上調至97美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論